Axogen Inc Cash Flow Conversion Efficiency
Axogen Inc cash flow conversion efficiency. Based on the latest financial reports, Axogen Inc (AXGN) has a cash flow conversion efficiency ratio of 0.006x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.56 Million) by net assets ($244.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Axogen Inc (1989–2025)
Cash flow conversion efficiency of Axogen Inc from 1989 to 2025. This chart illustrates how Axogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Axogen Inc stock price for real-time trading data and today's change.
Axogen Inc Cash Flow Conversion Ratio Explained
Axogen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Axogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axogen Inc ranked by their cash flow conversion efficiency. Also see AXGN market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Leadshine Technology Co Ltd
SHE:002979
|
0.074x |
|
Jizhong Energy Resources Co Ltd
SHE:000937
|
0.023x |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
0.037x |
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
-0.045x |
|
Liaoning Cheng Da Co Ltd
SHG:600739
|
0.005x |
|
Hubei Zhenhua Chemical Co Ltd
SHG:603067
|
0.013x |
|
Northwest Bancshares Inc
NASDAQ:NWBI
|
0.017x |
|
Hufvudstaden AB (publ)
ST:HUFV-A
|
0.013x |
Annual Cash Flow Conversion Efficiency for Axogen Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Axogen Inc from 1989 to 2025. Review Axogen Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $128.85 Million | $812.00K | 0.006x | -85.56% |
| 2024-12-31 | $103.91 Million | $4.54 Million | 0.044x | +173.05% |
| 2023-12-31 | $95.67 Million | $-5.72 Million | -0.060x | +62.44% |
| 2022-12-31 | $101.00 Million | $-16.07 Million | -0.159x | -33.56% |
| 2021-12-31 | $112.55 Million | $-13.40 Million | -0.119x | -52.37% |
| 2020-12-31 | $123.15 Million | $-9.63 Million | -0.078x | +48.02% |
| 2019-12-31 | $132.15 Million | $-19.87 Million | -0.150x | -23.74% |
| 2018-12-31 | $146.98 Million | $-17.86 Million | -0.122x | +66.87% |
| 2017-12-31 | $25.18 Million | $-9.24 Million | -0.367x | +51.15% |
| 2016-12-31 | $14.92 Million | $-11.20 Million | -0.751x | +52.85% |
| 2015-12-31 | $8.20 Million | $-13.05 Million | -1.593x | -271.36% |
| 2014-12-31 | $-11.25 Million | $-10.45 Million | 0.929x | +101.22% |
| 2013-12-31 | $136.63K | $-10.44 Million | -76.444x | -2597.08% |
| 2012-12-31 | $-2.83 Million | $-8.66 Million | 3.061x | +362.55% |
| 2011-12-31 | $6.07 Million | $-7.08 Million | -1.166x | -381.30% |
| 2010-12-31 | $10.03 Million | $-2.43 Million | -0.242x | -117.35% |
| 2009-12-31 | $11.06 Million | $15.44 Million | 1.396x | +192.99% |
| 2008-12-31 | $313.19K | $-470.16K | -1.501x | -188.97% |
| 2007-12-31 | $898.82K | $-466.95K | -0.520x | -2239.79% |
| 2006-12-31 | $1.30 Million | $-28.79K | -0.022x | +94.79% |
| 2005-12-31 | $1.66 Million | $-709.62K | -0.426x | -210.74% |
| 2004-12-31 | $2.28 Million | $878.84K | 0.385x | +116.91% |
| 2003-12-31 | $-153.77K | $-27.30K | 0.178x | +122.73% |
| 2002-12-31 | $966.80K | $-755.02K | -0.781x | +5.42% |
| 2001-12-31 | $3.54 Million | $-2.92 Million | -0.826x | -206.41% |
| 2000-12-31 | $4.72 Million | $-1.27 Million | -0.269x | -721.89% |
| 1999-12-31 | $6.10 Million | $-200.00K | -0.033x | -118.36% |
| 1998-12-31 | $8.40 Million | $1.50 Million | 0.179x | +1471.43% |
| 1997-12-31 | $8.80 Million | $100.00K | 0.011x | -38.07% |
| 1996-12-31 | $10.90 Million | $200.00K | 0.018x | +105.50% |
| 1995-12-31 | $11.20 Million | $100.00K | 0.009x | 0.00% |
| 1994-12-31 | $11.20 Million | $100.00K | 0.009x | -67.26% |
| 1993-12-31 | $11.00 Million | $300.00K | 0.027x | -79.94% |
| 1992-12-31 | $10.30 Million | $1.40 Million | 0.136x | +19.86% |
| 1991-12-31 | $9.70 Million | $1.10 Million | 0.113x | -23.24% |
| 1990-12-31 | $8.80 Million | $1.30 Million | 0.148x | +69.89% |
| 1989-12-31 | $6.90 Million | $600.00K | 0.087x | -- |
About Axogen Inc
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed periphera… Read more